-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $70

Benzinga·10/29/2026 13:22:19
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $50 to $70.